2-240873996-C-T
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM2PP3_StrongPP5_Very_Strong
The NM_000030.3(AGXT):c.614C>T(p.Ser205Leu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000274 in 1,461,356 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_000030.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251126Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135792
GnomAD4 exome AF: 0.00000274 AC: 4AN: 1461356Hom.: 0 Cov.: 31 AF XY: 0.00000138 AC XY: 1AN XY: 726982
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Primary hyperoxaluria, type I Pathogenic:4
- -
- -
- -
Variant_type:missense/MutationTaster:Disease_causing/CADD:Damaging/phyloP:Conserved/phastCons:Nonconserved/gnomAD_exome_EastAsian:0/ExAC_EastAsian:0/dbSNP:rs180177248 -
Primary hyperoxaluria Pathogenic:1
Variant summary: AGXT c.614C>T (p.Ser205Leu) results in a non-conservative amino acid change located in the Aminotransferase class V domain (IPR000192) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4e-06 in 251126 control chromosomes. c.614C>T has been reported in the literature as homozygous and compound heterozygous genotypes in individuals affected with Primary Hyperoxaluria Type 1 (example, Li_2018, Birtel_2019, Chen_2021, Zhao_2020). These data indicate that the variant is likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function (Williams_2009). The most pronounced variant effect results in <3% of normal alanine:glyoxylate aminotransferase (AGT) activity in vitro. One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation and classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
not provided Pathogenic:1
This sequence change replaces serine, which is neutral and polar, with leucine, which is neutral and non-polar, at codon 205 of the AGXT protein (p.Ser205Leu). This variant is present in population databases (rs180177248, gnomAD 0.0009%). This missense change has been observed in individuals with primary hyperoxaluria type 1 (PMID: 27935012, 30541997, 32556641). ClinVar contains an entry for this variant (Variation ID: 204118). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt AGXT protein function. For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Ser205 amino acid residue in AGXT. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 2039493; Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Experimental studies have shown that this missense change affects AGXT function (PMID: 19479957). -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at